Search

Displaying results 121 - 130 of 3917 in total
  1. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  2. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  3. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

  4. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized

  5. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

  6. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    Its primary indication is for bone imaging. … Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa

    Synonyms: Fluoride ion F-18
  7. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346]. … Most children with XLH suffer from bowed or bent legs, short stature, bone pain and severe dental pain.

    Categories: Drugs for Treatment of Bone Diseases, Drugs Affecting Bone Structure and Mineralization
  8. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [A256778] Abaloparatide is an osteoanabolic agent that stimulates bone formation. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.

    Categories: Bone Density Conservation Agents
  9. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

  10. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … breast and non-small-cell lung cancers.